First published February 1, 2012 - More info
Original citation: J. Clin. Invest. 2011;121(11):4348–4361. doi:10.1172/JCI46475.
Citation for this corrigendum: J. Clin. Invest. 2012;122(2):779. doi:10.1172/JCI62538.
In Figure 2, concentrations of the recombinant Hsp90α added to the real wounds in mice were inaccurate. The correct figure and legend appear below.
F-5 is superior to FDA-approved becaplermin/PDGF-BB in acute wound healing. Full-thickness skin wounds (1 cm × 1 cm) in athymic nude mice were treated (only once on day 0) with either 200 μl of 5% CMC gel (placebo) or the same volume of the gel containing an optimized concentration of a given peptide: (A) full-length, (B) F-2, (C) F-5, (D) F-6 (n = 3 mice per peptide, per experiment), or (E) becaplermin (20 μg of PDGF-BB or 8 μM). Plus signs indicate treated mice, and minus signs indicate placebo mice. The images of 1 representative experiment are shown.
The authors regret the error.